» Articles » PMID: 27899977

NaHCO Enhances the Antitumor Activities of Cytokine-induced Killer Cells Against Hepatocellular Carcinoma HepG2 Cells

Overview
Journal Oncol Lett
Specialty Oncology
Date 2016 Dec 1
PMID 27899977
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The extracellular pH is lower inside solid tumors than in normal tissue. The acidic environment inhibits the cytotoxicity of lymphocytes and promotes tumor cell invasion. In the present study, both and experiments were conducted to investigate how NaHCO would affect the antitumor activities of cytokine-induced killer (CIK) cells against hepatocellular carcinoma (HCC) cells. For the experiments, HepG2 cells were cultured at pH 6.5 and 7.4 in the presence of CIK cells or CIK cell-conditioned medium (CM). For the experiments, nude mice were xenografted with HepG2-luc cells and divided into four groups: i) CIK cells injection plus NaHCO feeding; ii) CIK cells injection plus drinking water feeding; iii) normal saline injection plus NaHCO feeding; and iv) normal saline injection plus drinking water feeding. The results indicated that the viability and growth rate of HepG2 cells were remarkably suppressed when co-cultured with CIK cells or CM at pH 7.4 compared with those of HepG2 cells cultured under the same conditions but at pH 6.5. In the xenograft study, a marked synergistic antitumor effect of the combined therapy was observed. NaHCO feeding augmented the infiltration of cluster of differentiation 3-positive T lymphocytes into the tumor mass. Taken together, these data strongly suggest that the antitumor activities of CIK cells against HepG2 cells were negatively affected by the acidic environment inside the tumors, and neutralizing the pH (for example, via NaHCO administration), could therefore reduce or eliminate this influence. In addition, it should be recommended that oncologists routinely prescribe soda water to their patients, particularly during CIK cell therapy.

Citing Articles

Recent advances of anti-tumor nano-strategies via overturning pH gradient: alkalization and acidification.

Gong Q, Song X, Tong Y, Huo L, Zhao X, Han Y J Nanobiotechnology. 2025; 23(1):42.

PMID: 39849540 PMC: 11761731. DOI: 10.1186/s12951-025-03134-2.


Tumor perfusion enhancement by microbubbles ultrasonic cavitation reduces tumor glycolysis metabolism and alleviate tumor acidosis.

Qiu D, He Y, Feng Y, Lin M, Lin Z, Zhang Z Front Oncol. 2024; 14:1424824.

PMID: 39091919 PMC: 11291205. DOI: 10.3389/fonc.2024.1424824.


Lactate in Sarcoma Microenvironment: Much More than just a Waste Product.

Taddei M, Pietrovito L, Leo A, Chiarugi P Cells. 2020; 9(2).

PMID: 32102348 PMC: 7072766. DOI: 10.3390/cells9020510.


Spatiotemporal pH Heterogeneity as a Promoter of Cancer Progression and Therapeutic Resistance.

Korenchan D, Flavell R Cancers (Basel). 2019; 11(7).

PMID: 31330859 PMC: 6678451. DOI: 10.3390/cancers11071026.


Targeting tumor-associated acidity in cancer immunotherapy.

Lacroix R, Rozeman E, Kreutz M, Renner K, Blank C Cancer Immunol Immunother. 2018; 67(9):1331-1348.

PMID: 29974196 PMC: 11028141. DOI: 10.1007/s00262-018-2195-z.

References
1.
Xie F, Zhang X, Li H, Zheng T, Xu F, Shen R . Adoptive immunotherapy in postoperative hepatocellular carcinoma: a systemic review. PLoS One. 2012; 7(8):e42879. PMC: 3419734. DOI: 10.1371/journal.pone.0042879. View

2.
Su Y, Yang Y, Ma Y, Zhang Y, Rao W, Yang G . The Efficacy and Safety of Dendritic Cells Co-Cultured with Cytokine-Induced Killer Cell Therapy in Combination with TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma: a Meta-Analysis. Clin Lab. 2016; 62(4):599-608. DOI: 10.7754/clin.lab.2015.150804. View

3.
Miao L, Run-Ming J, Yi J . T-Bet Mediated Anti-Neoplastic Effects of Dendritic Cell-Cytokine Induced Killer Cells in vitro. Iran J Pediatr. 2012; 22(1):43-51. PMC: 3448214. View

4.
Wojtkowiak J, Verduzco D, Schramm K, Gillies R . Drug resistance and cellular adaptation to tumor acidic pH microenvironment. Mol Pharm. 2011; 8(6):2032-8. PMC: 3230683. DOI: 10.1021/mp200292c. View

5.
Zhang L, Zhu W, Li J, Yang X, Ren Y, Niu J . Clinical outcome of immunotherapy with dendritic cell vaccine and cytokine-induced killer cell therapy in hepatobiliary and pancreatic cancer. Mol Clin Oncol. 2016; 4(1):129-133. PMC: 4727101. DOI: 10.3892/mco.2015.660. View